Shares of Bone Therapeutics dive on PhIII cell therapy failure; GSK-backed Sitryx inks discovery deal
→ Shares of Bone Therapeutics took a nasty, 26% hit $BOTHE after researchers hit the brakes on a Phase III study of their cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
